Skip to main content
. 2021 Dec 2;8:620354. doi: 10.3389/fcvm.2021.620354

Figure 1.

Figure 1

Prevalence of the ARC-HBR criteria in the HBR group. ARC, Academic Research Consortium; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; ICH, intracerebral hemorrhage; NSAIDs, non-steroidal anti-inflammatory drugs.